These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 36407837)

  • 1. Proteolysis and Deficiency of α1-Proteinase Inhibitor in SARS-CoV-2 Infection.
    Akbasheva OE; Spirina LV; Dyakov DA; Masunova NV
    Biochem Mosc Suppl B Biomed Chem; 2022; 16(4):271-291. PubMed ID: 36407837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Proteolysis and deficiency of α1-proteinase inhibitor in SARS-CoV-2 infection].
    Akbasheva OE; Spirina LV; Dyakov DA; Masunova NV
    Biomed Khim; 2022 Jun; 68(3):157-176. PubMed ID: 35717581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Host Cell Proteases to Prevent SARS-CoV-2 Invasion.
    Kaur U; Chakrabarti SS; Ojha B; Pathak BK; Singh A; Saso L; Chakrabarti S
    Curr Drug Targets; 2021; 22(2):192-201. PubMed ID: 32972339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-2 macroglobulin activity in SARS-CoV-2 induced infection and in the post-COVID-19 period.
    Akbasheva OE; Mitrofanova DK; Spirina LV; Samoilova YG; Matveeva MV; Podchinenova DV; Oleynik OA
    Biomed Khim; 2023 Sep; 69(4):240-247. PubMed ID: 37705485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SPARTA clinical trial design: exploring the efficacy and safety of two dose regimens of alpha1-proteinase inhibitor augmentation therapy in alpha1-antitrypsin deficiency.
    Sorrells S; Camprubi S; Griffin R; Chen J; Ayguasanosa J
    Respir Med; 2015 Apr; 109(4):490-9. PubMed ID: 25727857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. d-Galactose treatment increases ACE2, TMPRSS2, and FURIN and reduces SERPINA1 mRNA expression in A549 human lung epithelial cells.
    Baristaite G; Gurwitz D
    Drug Dev Res; 2022 May; 83(3):622-627. PubMed ID: 34677831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Silico Analysis Reveals the Inhibitory Potential of Madecassic Acid against Entry Factors of SARS-CoV-2.
    Ganguly A; Mandi M; Dutta A; Rajak P
    ACS Appl Bio Mater; 2023 Feb; 6(2):652-662. PubMed ID: 36608326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the efficacy of Alpha
    Pierce LR
    Heliyon; 2024 Jun; 10(11):e31183. PubMed ID: 38912501
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 strategically mimics proteolytic activation of human ENaC.
    Anand P; Puranik A; Aravamudan M; Venkatakrishnan AJ; Soundararajan V
    Elife; 2020 May; 9():. PubMed ID: 32452762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the pathogenesis of the adult respiratory distress syndrome.
    McGuire WW; Spragg RG; Cohen AB; Cochrane CG
    J Clin Invest; 1982 Mar; 69(3):543-53. PubMed ID: 7037851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sars-Cov2 Induced Biochemical Mechanisms in Liver Damage and Intestinal Lesions.
    Spirina LV; Masunov VN; Dyakov DA; Akbasheva OE; Kebekbayeva AY; Shuvalov IY; Masunova NV; Kovaleva IV; Dagbaeva Y
    Indian J Clin Biochem; 2022 Nov; 38(4):1-10. PubMed ID: 36407686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Camostat Does Not Inhibit the Proteolytic Activity of Neutrophil Serine Proteases.
    Assylbekova A; Zhanapiya A; Grzywa R; Sienczyk M; Schönbach C; Burster T
    Pharmaceuticals (Basel); 2022 Apr; 15(5):. PubMed ID: 35631327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid inactivation of alpha-1-proteinase inhibitor by neutrophil specific leukolysin/membrane-type matrix metalloproteinase 6.
    Nie J; Pei D
    Exp Cell Res; 2004 Jun; 296(2):145-50. PubMed ID: 15149845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term clinical outcomes following treatment with alpha 1-proteinase inhibitor for COPD associated with alpha-1 antitrypsin deficiency: a look at the evidence.
    Rahaghi FF; Miravitlles M
    Respir Res; 2017 May; 18(1):105. PubMed ID: 28558837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Feasible Alternative Strategy Targeting Furin Disrupts SARS-CoV-2 Infection Cycle.
    Mondal T; Shivange G; Habieb A; Tushir-Singh J
    Microbiol Spectr; 2022 Feb; 10(1):e0236421. PubMed ID: 35138160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human cell receptors: potential drug targets to combat COVID-19.
    Raghav PK; Kalyanaraman K; Kumar D
    Amino Acids; 2021 Jun; 53(6):813-842. PubMed ID: 33950300
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 mutation 614G creates an elastase cleavage site enhancing its spread in high AAT-deficient regions.
    Bhattacharyya C; Das C; Ghosh A; Singh AK; Mukherjee S; Majumder PP; Basu A; Biswas NK
    Infect Genet Evol; 2021 Jun; 90():104760. PubMed ID: 33556558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between α1-Antitrypsin Deficiency and SARS-CoV-2 Infection: Epidemiological Data and Pathogenetic Hypotheses.
    Vianello A; Guarnieri G; Braccioni F; Molena B; Lococo S; Achille A; Lionello F; Salviati L; Caminati M; Senna G
    J Clin Med; 2021 Sep; 10(19):. PubMed ID: 34640510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart.
    Liu H; Gai S; Wang X; Zeng J; Sun C; Zhao Y; Zheng Z
    Cardiovasc Res; 2020 Aug; 116(10):1733-1741. PubMed ID: 32638018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic potential of green tea catechin, (-)-epigallocatechin-3-
    Dinda B; Dinda S; Dinda M
    Phytomed Plus; 2023 Feb; 3(1):100402. PubMed ID: 36597465
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.